Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for NK Cell Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIR2DS4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIR2DS4 ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View KIR2DS4 Products |
| Gene Delivery | KIR2DS4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for functional activation assays. |
View KIR2DS4 Products |
| Benchmark Ab | Anti-KIR2DS4 Recombinant Antibody Recombinant positive control cloned from clinical benchmark sequences. |
View KIR2DS4 Products |
| Validator | KIR2DS4 siRNA Set For knockdown verification in primary NK cells or reporter lines. |
View KIR2DS4 Products |
| Related Target A | HLA-C Primary physiological ligand for KIR2DS4 (specifically HLA-C*04:01). Essential for binding competition assays. |
View HLA-C Products |
| Related Target B | KIR2DL1 Inhibitory counterpart sharing high sequence homology. Critical for off-target counter-screening. |
View KIR2DL1 Products |
| Related Target C | CD16a Co-activating receptor on NK cells. Crucial for bispecific NK cell engager (NKCE) designs. |
View CD16a Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High homology cross-reactivity (KIR2DL1/L2/L3/S1/S2) | Homolog panel proteins strictly verified by mass spectrometry and sequence alignment. |
| Conformational stability of activating receptor | HEK293 mammalian expression system preserves native post-translational glycosylation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live KIR2DS4/CD158i R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIR2DS4 therapeutics is intensifying, with major players shifting focus from broad-spectrum immune checkpoint inhibitors to highly selective NK cell-activating modalities. As first-generation monoclonal antibodies targeting inhibitory KIRs (such as KIR2DL1/2/3) reach advanced clinical evaluation, the next wave of R&D is targeting activating KIRs like KIR2DS4 to directly trigger NK-mediated cytolysis. Future trends point toward bispecific/trispecific NK cell engagers (NKCEs) and CAR-NK applications where KIR2DS4 acts as a key activating engine, bypassing inhibitory signals in the immunosuppressive tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Agonist mAbs | Innate Pharma, Bristol Myers Squibb | Hematological Malignancies, Acute Myeloid Leukemia (AML) | Selectivity Screening (Need KIR2DS4 vs KIR2DL1/S1 proteins to ensure no inhibitory off-target activation) |
| NK Cell Engagers (NKCE) | Sanofi, Affimed | Solid Tumors, Refractory Lymphoma | Heterodimer/Multimer Validation (Need high-purity ECD-Fc fusion proteins to verify dual/triple antigen binding) |
| Cell Therapy (CAR-NK) | NantKwest, MD Anderson Cancer Center | Advanced Solid Tumors | Transduction & Expression Validation (Need Lentivirus Premade Particles for stable KIR2DS4 reporter line generation) |